GSK Nuvalent Acquisition: ROS1/ALK NSCLC TKI Pipeline
Analyze GSK’s $10.6B Nuvalent acquisition. Learn about zidesamtinib & neladalkib, their clinical trial data, and the ROS1/ALK NSCLC competitive landscape.
Back to Articles
Articles tagged with “precision-oncology”
Basket vs. Umbrella Trials: Master Protocols Explained
Learn the definitions and key differences between basket, umbrella, and platform trials. This guide explains how master protocols work in precision oncology, including 2025-2026 updates on tissue-agnostic approvals, NCI successor trials (ComboMATCH, MyeloMATCH), and evolving FDA guidance.